- Conditions
- COVID-19
- Interventions
- Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,439
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endothelial Dysfunction, Hypertension
- Interventions
- Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
- Drug · Dietary Supplement
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Postoperative Pain
- Interventions
- Oxytocin, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- Reslizumab, Saline
- Biological · Other
- Lead sponsor
- Ception Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 24
- States / cities
- Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- COVID-19
- Interventions
- Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Critical Illness, Acute Kidney Injury
- Interventions
- 0.9% Saline, Physiologically-balanced isotonic crystalloid
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Coronary Artery Disease, Sternal Pain
- Interventions
- Bupivacaine Group, Placebo
- Drug · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
- Conditions
- Obesity, Pain
- Interventions
- Acetaminophen, Placebo
- Drug
- Lead sponsor
- Trinity Health Of New England
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
- Biological · Other · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
- Conditions
- Epistaxis
- Interventions
- Tranexamic Acid, Placebo
- Drug · Other
- Lead sponsor
- Mercy Health Ohio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Boardman, Ohio • Youngstown, Ohio
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Depemokimab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 961 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 56
- States / cities
- Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more
- Conditions
- Complex Regional Pain Syndrome
- Interventions
- Ketamine Infusion + Epidural Infusion, Control Group + Epidural infusion, Ketamine Booster Infusion, Control Group Booster Infusion
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV-associated Myelopathy
- Interventions
- Intravenous Immunoglobulin, Placebo
- Drug
- Lead sponsor
- David M. Simpson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Adhesive Small Bowel Obstruction
- Interventions
- Gastrografin, Saline, SBO Treatment Without NG Tubes
- Drug · Procedure
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
- Interventions
- Suprainguinal fascia iliaca (SIFI) block, Sham block, Ropivacaine, Saline
- Procedure · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Coagulation; Intravascular, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Tranexamic Acid, Total Hip Arthroplasty
- Interventions
- Tranexamic Acid, Placebo
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Marijuana Dependence
- Interventions
- Oxytocin, Saline
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Quality of Recovery Scores
- Interventions
- Methadone, Saline
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Tendonitis;Achilles
- Interventions
- Micronized DHACM, Saline Injection
- Biological · Drug
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more
- Conditions
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
- Interventions
- DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more